Factor XI Deficiency and Hemophilia C in Dogs: A Complete Guide

Hemophilia is a genetic blood clotting disorder that affects multiple mammals, including both dogs and humans. The condition varies by type and cause but is inherited from parent dogs to their puppies, impairing the body's ability to form clots and heal wounds properly.

Some dog breeds have reported cases of hemophilia that pose genuine health concerns. One breed notably associated with factor XI deficiency, which causes hemophilia C, is the Kerry Blue Terrier puppies. Factor XI is an essential protein in blood clotting, and a deficiency can lead to bleeding problems. Although hemophilia C remains relatively rare, awareness benefits breeding practices and overall canine health in the U.S.

What is factor XI deficiency?

Factor XI is a naturally occurring protein in blood that plays a crucial role in clot formation and wound recovery. Dogs affected by factor XI deficiency produce lower than normal levels of this protein, resulting in extended bleeding times and delayed healing after injury.

Contrary to some bleeding disorders that cause rapid blood loss, factor XI deficiency slows the clotting process, which means that wounds bleed for a longer duration. The severity of symptoms can vary widely—some affected dogs may show mild signs and only experience problems when injured or undergoing surgery.

Understanding hemophilia C in dogs

Hemophilia refers to a group of inherited diseases where blood clotting is hindered due to absent or deficient clotting factors. Specifically, hemophilia C in dogs occurs because of a shortage of factor XI. While generally less severe than hemophilia A and B, it can still lead to dangerous bleeding episodes.

Dogs with hemophilia C might seem healthy at birth but can face unexpected bleeding after trauma or surgical procedures. Early identification and management equip owners and breeders with tools to minimize health risks.

Breeds at risk and inheritance patterns

Beyond the Kerry Blue Terrier, factor XI deficiency and hemophilia C have been documented in U.S. breeds such as the Springer Spaniel, Great Pyrenees, and Weimaraner. The condition affects both males and females equally, following an autosomal recessive inheritance pattern.

For a dog to inherit hemophilia C, it must receive two copies of the defective gene, one from each parent. Dogs are classified as clear (no copies), carriers (one copy), or affected (two copies). Understanding these genetic categories is essential for responsible breeding.

• Two clear parents produce all clear puppies.
• Two affected parents produce only affected puppies.
• Breeding two carriers results in 25% affected, 50% carriers, and 25% clear puppies.
• Clear bred with affected yields 100% carriers.
• Clear paired with carrier produces 50% clear and 50% carriers.
• Carrier bred to affected results in 50% affected and 50% carriers.

Testing and responsible breeding in the US

Though factor XI deficiency is uncommon, genetic testing is available through multiple U.S. veterinary laboratories including the University of Pennsylvania's PennGen, Orthopedic Foundation for Animals (OFA), Embark, and Paw Print Genetics. These tests support informed mating, especially when screening dogs related to diagnosed cases.

Unlike the UK’s Kennel Club, no mandatory testing programs currently exist for factor XI deficiency in breeds like the Kerry Blue Terrier in the U.S. However, proactive health screening is strongly encouraged to promote breed health and reduce heritable diseases. American breeders benefit from education on this condition and the importance of ethical practices.

Managing dogs with factor XI deficiency

With attentive care, dogs diagnosed with factor XI deficiency can live normal, happy lives. It is vital that owners notify their veterinarians if their dog is affected, particularly before surgery, dental procedures, or other invasive treatments to avoid complications from bleeding.

Treatment during bleeding events often involves transfusions of fresh frozen plasma or blood products to provide the missing clotting factors. Additionally, antifibrinolytic medications like tranexamic acid can help control bleeding. While gene therapy has shown promise for hemophilia A and B, it remains experimental for factor XI deficiency. Veterinary guidance ensures each dog's treatment plan is tailored for the best quality of life.

Conclusion

Though rare, factor XI deficiency and hemophilia C deserve attention from both U.S. breeders and owners, particularly in breeds such as the Kerry Blue Terrier, Springer Spaniel, Great Pyrenees, and Weimaraner. Understanding inheritance patterns, utilizing genetic testing, and responsibly managing affected dogs help decrease risk and improve health outcomes.

Prospective owners and breeders should seek reputable genetic screening and collaborate closely with veterinarians. Encouraging knowledgeable, ethical breeding in the U.S. supports healthier future generations of dogs.